Notably, PMAIP1 and BAX mutations were recently reported in CLL patients that relapsed on VEN monotherapy.31 Silencing of additional genes, including OMA1, GLUL, KIAA0141, and CHST9 also lead to VEN resistance (Supplementary Fig. 5k). The gene discussed is CHST9; the disease is B-cell chronic lymphocytic leukemia.